Evidence map›Paper›PMID 9151680›Full record

ArticleThe Journal of cell biology1997

Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy.

W Yu, J Kim, L Ossowski

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of cell biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 155 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Hypoxia and Bone Metastatic Disease.Current osteoporosis reports · 2017
    Review
  6. Melanoma and brown seaweed: an integrative hypothesis.Journal of applied phycology · 2017
    Article
  7. Article
  8. Article
  9. Review
  10. Metastasis review: from bench to bedside.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Controversies in clinical cancer dormancy.Proceedings of the National Academy of Sciences of the United States of America · 2011
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

W YuDepartment of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
J Kim
L Ossowski
Icahn School of Medicine at Mount Sinai · USChemotherapy Foundation · US

Funding

FACTORS INVOLVED IN MALIGNANT BEHAVIOR OF HUMAN TUMORSR01CA040758 · NCI · ROCKEFELLER UNIVERSITY · PI OSSOWSKI, LILIANA · 1985 to 2007
$2.6M
NCI NIH HHS CA-40758NCI NIH HHS R01 CA040758
6 · The paper itself

Abstract

Considerable evidence links urokinase plasminogen activator (uPA) bound to its surface receptor (uPAR) with enhanced invasiveness of cancer cells. By blocking uPAR expression in human epidermoid carcinoma cells (HEp3), we have now identified an additional and novel in vivo function for this receptor by showing that receptor-deficient cells enter a state of dormancy reminiscent of that observed in human cancer metastasis. Its main characteristic is survival without signs of progressive growth. Five clones transfected with a vector expressing uPAR antisense RNA under the beta-actin promoter were isolated and shown to have uPAR (at the mRNA and protein levels) reduced by 50 to 80%; four clones, transfected with vector alone and having uPAR levels similar to those of parental cells, served as controls. In confirmation of our previous results, reduced uPAR always coincided with a significantly reduced invasiveness. Each of the control clones produced rapidly growing, highly metastatic tumors within 2 wk of inoculation on chorioallantoic membranes (CAMs) of chick embryos. In contrast, each of the clones with low surface uPAR, whose proliferation rate in culture was indistinguishable from controls, remained dormant for up to 5 mo when inoculated on CAMs. Thus, the reduction in uPAR altered the phenotype of HEp3 tumor cells from tumorigenic to dormant. Although protracted, tumor dormancy was not permanent since in spite of maintaining low uPAR levels, each of the in vivo-passaged antisense clones eventually reemerged from dormancy to initiate progressive growth and to form metastases at a level of 20 to 90% of that of fully malignant control. This observation suggested that other factors, whose expression is dependent on cumulative and prolonged in vivo effects, can compensate for the lack of a full complement of surface uPAR required for the expression of malignant properties. These "reemerged," uPAR-deficient clones were easily distinguishable from the vector-transfected controls by the fact that after only 1 wk in culture, the invasion of CAM by all five clones and tumorigenicity of four of the five clones were reduced back to the values observed before in vivo maintenance. In contrast, dissociated and in vitro-grown cells of control tumors were fully invasive and produced large, metastatic tumors when reinoculated on CAMs. Quantitation of the percent of apoptotic and S-phase cells in vivo, in the control and uPAR-deficient, dormant clones, showed that the mechanism responsible for the dormancy was a diminished proliferation.

Indexed as

ApoptosisCell DivisionDNA, NeoplasmDown-RegulationHumansNecrosisNeoplasm InvasivenessNeoplasm MetastasisReceptors, Cell SurfaceReceptors, Urokinase Plasminogen ActivatorRNA, AntisenseTumor Cells, CulturedUrokinase-Type Plasminogen ActivatorDNA, NeoplasmPLAUR protein, humanReceptors, Cell SurfaceReceptors, Urokinase Plasminogen ActivatorRNA, AntisenseUrokinase-Type Plasminogen Activator

Identifiers

PMID9151680
PMCPMC2139877
OpenAlexW2011304249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.